Literature DB >> 33387086

Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients.

Feiling Feng1, Xiaobing Wu1, Xiaoliang Shi2, Qingxiang Gao1, Yue Wu1, Yong Yu1, Qingbao Cheng1, Bin Li1, Bin Yi1, Chen Liu1, Qing Hao2, Lin Zhang2, Chunfang Gao3, Xiaoqing Jiang4.   

Abstract

BACKGROUND: Cholangiocarcinoma (CCA) is a rare malignant tumor of the biliary system. The heterogeneity of CCA leads to the lack of effective targeted treatment for CCA subtypes. The molecular characteristic of hilar CCA (hCCA) is still unclear.
METHODS: A total of 63 hCCA patients were enrolled from Shanghai Eastern Hepatobiliary Surgery Hospital. Formalin-fixed, paraffin-embedded tumor tissues, and matched blood were collected and deep sequencing targeting 450 cancer genes were performed. Tumor mutation burden (TMB) was measured by an algorithm developed in-house. Correlation analysis was performed by Fisher's exact test.
RESULTS: The most commonly mutated genes were TP53 (51.7%), NF1 and KRAS (20%, for both), SMAD4 (16.7%), FAT3 and FRS2 (13.3%, for both), NF1 (11.7%), and KMT2C, MDM2, and ATM (10%, for each) in hCCA. ARID1A, GATA6, and PREX2 mutations commonly occurred in female and KMT2C mutations mainly occurred in patients under 60 years old. Statistical analysis showed the association between ARID1A mutation and tumor stage (P = 0.041) and between NF1 mutation and high TMB (P = 0.0095). Furthermore, ARID1B mutation was identified to associate with the poor prognosis of Chinese hCCA patients (P = 0.004).
CONCLUSION: The mutational characterization of hCCA is different from both extrahepatic CCA and intrahepatic CCA. ARID1B is a potential biomarker for prognosis prediction of Chinese hCCA patients.

Entities:  

Keywords:  Biomarker; Cholangiocarcinoma; Disease-free survival; Genomic alteration; Tumor mutational burden

Year:  2021        PMID: 33387086     DOI: 10.1007/s10147-020-01846-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  51 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Authors:  John D Hainsworth; Funda Meric-Bernstam; Charles Swanton; Herbert Hurwitz; David R Spigel; Christopher Sweeney; Howard Burris; Ron Bose; Bongin Yoo; Alisha Stein; Mary Beattie; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2018-01-10       Impact factor: 44.544

3.  Surgery for hilar cholangiocarcinoma: the Leeds experience.

Authors:  E Hidalgo; S Asthana; H Nishio; J Wyatt; G J Toogood; K R Prasad; J P A Lodge
Journal:  Eur J Surg Oncol       Date:  2007-11-26       Impact factor: 4.424

Review 4.  Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers.

Authors:  Jun Du; Xiao-Jun Zhou
Journal:  Crit Rev Oncog       Date:  2017

Review 5.  Pathogenesis, diagnosis, and management of cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Gastroenterology       Date:  2013-10-15       Impact factor: 22.682

6.  Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom.

Authors:  Matthew T Huggett; Helen Passant; Chris Hurt; Stephen P Pereira; John Bridgewater; Somnath Mukherjee
Journal:  Tumori       Date:  2014 Mar-Apr

7.  Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.

Authors:  Chaitanya R Churi; Rachna Shroff; Ying Wang; Asif Rashid; HyunSeon C Kang; Jacqueline Weatherly; Mingxin Zuo; Ralph Zinner; David Hong; Funda Meric-Bernstam; Filip Janku; Christopher H Crane; Lopa Mishra; Jean-Nicholas Vauthey; Robert A Wolff; Gordon Mills; Milind Javle
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

8.  Proximal Resection Margins: More Prognostic than Distal Resection Margins in Patients Undergoing Hilar Cholangiocarcinoma Resection.

Authors:  Tae Yoo; Sang-Jae Park; Sung-Sik Han; Seong Hoon Kim; Seung Duk Lee; Tae Hyun Kim; Soon-Ae Lee; Sang Myung Woo; Woo Jin Lee; Eun Kyung Hong
Journal:  Cancer Res Treat       Date:  2017-11-16       Impact factor: 4.679

9.  Comprehensive genomic profile of cholangiocarcinomas in China.

Authors:  Weijun Tian; Weiyu Hu; Xiaoling Shi; Peng Liu; Xiang Ma; Wei Zhao; Linlin Qu; Shuirong Zhang; Weiwei Shi; Angen Liu; Jingyu Cao
Journal:  Oncol Lett       Date:  2020-03-03       Impact factor: 2.967

10.  Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma.

Authors:  Peizhan Chen; Bin Li; Yan Zhu; Wei Chen; Xin Liu; Mian Li; Xiaohua Duan; Bin Yi; Jinghan Wang; Chen Liu; Xiangji Luo; Xiaoguang Li; Jingquan Li; Lijian Liang; Xiaoyu Yin; Hui Wang; Xiaoqing Jiang
Journal:  Oncotarget       Date:  2016-06-14
View more
  3 in total

1.  Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma.

Authors:  Yuanwen Zheng; Yejun Qin; Wei Gong; Hongguang Li; Bin Li; Yu Wang; Baoting Chao; Shulei Zhao; Luguang Liu; Shuzhan Yao; Junping Shi; Xiaoliang Shi; Kai Wang; Shifeng Xu
Journal:  J Gastrointest Oncol       Date:  2021-12

2.  Quantitative detections of TP53 gene mutations improve the diagnosis and prognostic prediction of biliary tract cancers using droplet digital PCR.

Authors:  Xiao Xiao; Jun Zhou; Meng Fang; Jun Ji; Chenjun Huang; Fei Du; Wenchao Ai; Ying Wang; Zhiyuang Gao; Zhiquan Qiu; Chunfang Gao
Journal:  J Clin Lab Anal       Date:  2021-11-23       Impact factor: 2.352

3.  Expression Signature of the AT-Rich Interactive Domain Gene Family Identified in Digestive Cancer.

Authors:  Yongqu Lu; Zhenzhen Liu; Wendong Wang; Xin Chen; Xin Zhou; Wei Fu
Journal:  Front Med (Lausanne)       Date:  2022-01-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.